

Chemical Science

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Targeting Virulence: Salmochelin Modification Tunes the Antibacterial Activity Spectrum of β -Lactams for Pathogen-Selective Killing of *Escherichia coli*

Phoom Chairatana, Tengfei Zheng, and Elizabeth M. Nolan*

Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

*Corresponding author: lnolan@mit.edu

Phone: 617-452-2495

Fax: 617-324-0505

Abstract

New antibiotics are required to treat bacterial infections and counteract the emergence of antibiotic resistance. Pathogen-specific antibiotics have several advantages over broad-spectrum drugs, which include minimal perturbation to the commensal microbiota. We present a strategy for targeting antibiotics to bacterial pathogens that utilizes the salmochelin-mediated iron uptake machinery of Gram-negative *Escherichia coli*. Salmochelins are C-glucosylated derivatives of the siderophore enterobactin. The biosynthesis and utilization of salmochelins are important for virulence because these siderophores allow pathogens to acquire iron and evade the enterobactin-scavenging host-defense protein lipocalin-2. Inspired by the salmochelins, we report the design and chemoenzymatic preparation of glucosylated enterobactin- β -lactam conjugates that harbour the antibiotics ampicillin (Amp) and amoxicillin (Amx), hereafter GlcEnt-Amp/Amx. The GlcEnt scaffolds are based on mono- and diglucosylated Ent where one catechol moiety is functionalized at the C5 position for antibiotic attachment. We demonstrate that GlcEnt-Amp/Amx provide up to 1000-fold enhanced antimicrobial activity against uropathogenic *E. coli* relative to the parent β -lactams. Moreover, GlcEnt-Amp/Amx based on a diglucosylated Ent (DGE) platform selectively kill uropathogenic *E. coli* that express the salmochelin receptor Iron in the presence of non-pathogenic *E. coli* and other bacterial strains that include the commensal microbe *Lactobacillus rhamnosus* GG. Moreover, GlcEnt-Amp/Amx evade the host-defense protein lipocalin-2, and exhibit low toxicity to mammalian cells. Our work establishes that siderophore-antibiotic conjugates provide a strategy for targeting virulence, narrowing the activity spectrum of antibiotics in clinical use, and achieving selective delivery of antibacterial cargos to pathogenic bacteria on the basis of siderophore receptor expression.

Introduction

Bacterial infections, the rise in antibacterial resistance in hospital and community settings, and the paucity of new antibiotics in the current drug pipeline create a worldwide public health crisis.^{1,2} New strategies to diagnose and treat bacterial infections as well as counteract the emergence and spread of antibiotic resistance in bacterial pathogens are urgently needed to reduce morbidity and mortality, as well as the economic burden, caused by these infections.^{3,4} The discovery and advance of narrow-spectrum antibiotics that target select pathogens is one important and necessary facet of this large and complex problem.^{2,5,6} Pathogen-specific antibiotics that minimally perturb the normal microbial flora are expected to reduce the likelihood of colonisation by pathogenic and drug-resistant microbes during or after antibiotic treatment, and prevent life-threatening secondary infections such as those caused by *Clostridium difficile*.^{5,7} Moreover, the availability of narrow-spectrum antibiotics, coupled with rapid diagnostics, is expected to reduce the use of broad-spectrum therapeutics and thereby slow down the evolution of drug resistance.^{2,5,7} Among current and emerging microbial threats, Gram-negative bacteria, including pathogenic *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, and *Salmonella* spp., pose a challenge for antibiotic drug discovery.^{1,2,8} These strains have an outer membrane that serves as a permeability barrier and prevents the cellular entry of many antibiotics.⁹ In this work, we report a stealth antibiotic delivery strategy that overcomes the outer membrane permeability barrier of Gram-negative *Escherichia coli* and targets pathogenicity by hijacking the iron import machinery utilised by virulent strains during colonisation in the mammalian host.

Iron is an essential nutrient for almost all bacterial pathogens.^{10,11} Because iron exhibits low solubility in aqueous solutions at physiological pH and enables Fenton chemistry, the levels of “free” iron in mammals (ca. 10^{-24} M in serum)¹² are tightly regulated by homeostatic mechanisms, which include the expression of the iron-transport and storage proteins transferrin and ferritin.¹³ Most bacterial pathogens require micromolar concentrations of iron to colonise and cause disease, and bacterial iron acquisition machineries contribute to virulence.^{10,14}





Fig. 1. Siderophores and outer membrane siderophore receptors relevant to this work. (a) Chemical structures of enterobactin **1**, and its glucosylated derivatives **2-4**. (b) A cartoon representation of the outer membrane receptors FepA and IroN considered in this work. (c) Chemical structures of Ent-Amp/Amx **5-6**.

One way that bacteria scavenge iron in the host environment is to biosynthesize and export siderophores, secondary metabolites that chelate Fe(III) with high affinity.¹⁵ The ferric siderophores are recognised and transported into the cell by dedicated uptake machinery. In this work, we consider the catechol sideorophore enterobactin **1** (Ent, Fig. 1a), its glucosylated congeners **2-4** (GlcEnt, Fig. 1a), and the outer membrane receptors for these iron chelators. Ent is biosynthesized by all *E. coli* and the ferric complex is transported across the outer membrane by the TonB-ExbB-ExbD-dependent outer membrane receptor FepA (Fig. 1b).¹² In addition to Ent, many pathogenic *E. coli* as well as *Salmonella* spp. biosynthesize salmochelins, C-glucosylated derivatives of Ent (Fig. 1a).¹⁶ The *iroA* gene cluster (*iroBCDEN*)^{14,17,18} encodes enzymes that tailor the Ent scaffold to provide the salmochelins (IroBDE), and proteins for salmochelin transport (IroCN). Expression of genes encoded by the *iroA* locus contributes to virulence by providing Gram-negative pathogens with additional iron acquisition machinery and enabling the pathogens to overcome the host innate immune response.^{19,20} In the battle against such invading pathogens, the mammalian host mounts a metal-withholding response and secretes lipocalin-2 (Lcn2), a 22-kDa antimicrobial protein that captures ferric Ent.^{19,21,22} Gram-negative pathogens that utilize salmochelins for iron acquisition readily evade this innate immune mechanism because the salmochelins cannot be sequestered by Lcn2.¹⁹

Because bacteria utilize siderophores to acquire nutrient iron during infection, these molecules, as well as the corresponding biosynthetic and transport machineries, provide opportunities for antibiotic development.^{10,11,23-27} The notion of using siderophores or siderophore mimics to deliver antibacterial cargo into bacterial cells has garnered attention over several decades.²⁸⁻⁴⁴ Our approach to siderophore-based targeting focuses on harnessing native siderophore platforms used by pathogens in the human host for cargo delivery, and we seek to modify these scaffolds in ways that minimally perturb iron binding and receptor recognition. We have designed and utilised a monofunctionalized Ent platform to assemble a variety of Ent-cargo conjugates, and we reported that the Ent uptake machinery (FepABCDG) provides a means to transport small-molecule cargo, including antibiotics in clinical use, into *E. coli*.^{44,45} For instance, the Ent- β -lactam conjugates **5-6** (Fig. 1c) target and kill *E. coli* expressing FepA.⁴⁴ Because all *E. coli* use Ent for iron acquisition, the Ent- β -lactam conjugates target and kill both non-pathogenic and pathogenic *E. coli* strains. Some *E. coli* are commensal microbes, comprising <1% of the total microbial community in the human gut, and biosynthesize vitamin K that is needed by the host.^{46,47} Thus, the ability to target pathogenic *E. coli* has utility for minimally perturbing the normal flora. Inspired by prior investigations of native siderophore transport,^{16,48} we hypothesized that salmochelin-antibiotic conjugates will be specifically recognised by IroN, the outer membrane receptor for the salmochelins, and afford a strategy for overcoming the outer membrane permeability barrier, achieving narrow-spectrum antibacterial activity against pathogenic *E. coli*, and evading capture by Lcn2.

In this work, we report the design and chemoenzymatic preparation of siderophore- β -lactam conjugates based on salmochelin platforms, and demonstrate targeting of β -lactam antibiotics to pathogenic *E. coli* that harbour the *iroA* gene cluster and express IroN. Salmochelin-inspired GlcEnt- β -lactam conjugates based on the diglycosylated Ent (DGE, Fig. 1a) platform provide selective antibacterial activity against pathogenic *E. coli* and up to 1000-fold enhanced potency relative to the parent β -lactam antibiotics. Moreover, the salmochelin-inspired conjugates remain antibacterial in the presence of Lcn2. These investigations establish

a chemoenzymatic route to functionalized salmochelins and provide a new approach for transforming a broad-spectrum antibiotic in clinical use into a narrow-spectrum therapeutic that targets microbial pathogens on the basis of siderophore receptor expression.



Scheme 1. Chemoenzymatic syntheses of GlcEnt-Amp/Amx **7-10**. The synthetic route consists of MceC- or IroB-catalysed glycosylation of Ent-PGE₃-N₃ **11** followed by a copper-catalysed click reaction to achieve the GlcEnt-β-lactam conjugates **7-10**. We abbreviate the siderophore family **1-4** as (Glc)Ent and the siderophore-β-lactam conjugates **5-10** as (Glc)Ent-Amp/Amx.

Results and Discussion

Design and Syntheses of GlcEnt-β-Lactam Conjugates. We present a family of salmochelin-inspired GlcEnt-β-lactam conjugates **7-10** that exhibit ampicillin (Amp) or amoxicillin (Amx) attached to either monoglucosylated Ent (MGE, **2**) or diglucosylated Ent (DGE, **3**) by a stable polyethylene glycol (PEG₃) linker. The design of the GlcEnt-β-lactam conjugates **7-10** builds upon Ent-Amp/Amx **5-6** (Figure 1C).⁴⁴ These conjugates are based on a monosubstituted Ent platform where one catechol moiety is modified at the C5 position for cargo attachment. We

sought to install glucose moieties at the C5 position of one or both of the unfunctionalized catecholate rings to afford MGE-Amp/Amx **7-8** and DGE-Amp/Amx **9-10**, respectively. Although the total chemical syntheses of salmochelins have been reported, nine steps are required to achieve the requisite glucosylated 2,3-dihydroxybenzoic acid building block.⁴⁹ We therefore established a chemoenzymatic approach that employs enzymes involved in salmochelin biosynthesis, which affords the desired glucosylated conjugates and requires only one additional step compared to the reported preparation of Ent-Amp/Amx.

IroB and MceC are C-glucosyltransferases that catalyse C-glucosylation of Ent at the C5 positions of the catechol rings. MceC is encoded by the MccE492 gene cluster of *K. pneumoniae* RYC492, and has 75% amino acid sequence homology with IroB.⁵⁰ IroB catalyses up to three C-glucosylation events, affording MGE, DGE and TGE as products (Fig. 1a).⁵¹ MceC, in contrast, produces only MGE and DGE.⁵² On the basis of these observations, we hypothesized that both IroB and MceC would accept monofunctionalized Ent as a substrate, providing a preparative route to **7-10**. Initial activity assays where either IroB or MceC was incubated with Ent-PEG₃-N₃ **11**, UDP-Glc, and Mg(II) revealed that both enzymes accept Ent-PEG₃-N₃ **11** as a substrate and afford MGE-PEG₃-N₃ **12** and DGE-PEG₃-N₃ **13** as products (Figs. S1, S2). Accumulation of **12** was observed in the MceC-catalysed reactions, whereas **13** accumulated in reactions catalysed by IroB. When Ent-Amp/Amx **5-6** were employed as substrates, complex product mixtures were obtained. LC/MS analysis of the mixtures revealed the desired products as well as multiple byproducts, including products of β -lactam decomposition. We therefore performed large-scale C-glucosylation reactions employing Ent-PEG₃-N₃ **11** as a substrate to afford milligram quantities of MGE-PEG₃-N₃ **12**, and DGE-PEG₃-N₃ **13** (Scheme 1). We subsequently employed copper-catalysed azide/alkyne cycloaddition to install the β -lactam moieties (Scheme 1).⁴⁴ This route achieved the mono- and diglucosylated conjugates **7-10** in high purity and in yields of 26-59% from **7** following HPLC purification. As expected, the GlcEnt- β -lactam conjugates **7-10** bind iron.⁵³ Each Fe(III) complex exhibits a

broad absorption band (ca. 400-700 nm, MeOH) characteristic of ferric Ent and its derivatives (Fig. S3).^{44,45,54}

DGE- β -lactam Conjugates Target Pathogenic *E. coli* Expressing IroN. To evaluate whether GlcEnt-Amp/Amx **7-10** target pathogenic *E. coli* expressing IroN, we compared the antibacterial activities of the parent antibiotics Amp/Amx, Ent-Amp/Amx **5-6**, and GlcEnt-Amp/Amx **7-10**. We selected five *E. coli* strains on the basis of siderophore receptor expression (Table S1). *E. coli* CFT073⁵⁵ and UTI89⁵⁶ harbour the *iroA* gene cluster, biosynthesize and utilise salmochelins for iron acquisition in the host, and cause urinary tract infections.^{57,58} In contrast, *E. coli* H9049 is a clinical isolate that does not have the *iroA* cluster.²² *E. coli* K-12⁵⁹ and *E. coli* B⁶⁰ are non-pathogenic laboratory strains that also lack the *iroA* cluster. To ascertain the effect of iron limitation on antibacterial activity, we performed antibacterial activity assays in the absence or presence of the metal-ion chelator 2,2'-dipyridyl (DP, 200 μ M). This concentration of DP inhibits *E. coli* growth (Fig. S4). These assays revealed that DGE-Amp/Amx **9-10** target pathogenic *E. coli* that express IroN.

Amp/Amx exhibit minimum inhibitory concentration (MIC) values of 10 μ M against the five *E. coli* strains (\pm DP, Figs. 2, S5-S9). Under conditions of iron limitation, Ent-Amp/Amx provide 100- to 1000-fold enhanced activity against all five strains (50% MHB, +DP). These results are in agreement with our prior studies of Ent-Amp/Amx killing of *E. coli*.⁴⁴ Glucosylation affords strain-dependent antimicrobial activity that correlates with IroN expression (Figs. 2a,b, S5, S6). Like Ent-Amp/Amx **5-6**, GlcEnt-Amp/Amx **7-10** provide 100- and 1000-fold enhanced antimicrobial activity against *E. coli* UTI89 and *E. coli* CFT073, respectively (+DP). The susceptibility of *E. coli* CFT073 to GlcEnt-Amp/Amx remains enhanced in the absence of DP, as observed previously for Ent-Amp/Amx.⁴⁴ The antibacterial activity of GlcEnt-Amp/Amx **7-10** against *E. coli* H9049, K-12, and B is attenuated relative to that of Ent-Amp/Amx **5-6** (+DP, Figs. 2c-e, S7-S9). Moreover, for these non-pathogenic strains, the MIC values of (Glc)Ent-Amp/Amx follow the trend Ent-Amp/Amx < MGE-Amp/Amx < DGE-Amp/Amx. The MGE modification provides enhanced potency relative to Amp/Amx because growth reduction (K-12) or complete

growth inhibition (H9049 and B) occurs at 1 μM MGE-Amp/Amx (+DP). In contrast, the DGE- β -lactam conjugates exhibit negligible antibacterial activity against the three strains that lack IronN (MIC > 10 μM). The growth medium contains ≈ 4 μM iron (Table S2) and we attribute the growth inhibition observed at 10 μM DGE-Amp/Amx to iron deprivation that results from DGE-Amp/Amx sequestering the iron in the growth medium (Table S2).




Fig. 2. Antibacterial activity of (Glc)Ent-Amp against five *E. coli* strains. (a)-(e) Antibacterial activity of (Glc)Ent-Amp **5/7/9** against (a) uropathogenic *E. coli* CFT073, (b) uropathogenic *E. coli* UTI89, (c) non-pathogenic clinical isolate *E. coli* H9049, (d) laboratory strain *E. coli* K-12, (e) laboratory strain *E. coli* B. All assays were performed in 50% MHB medium supplemented with 200 μM DP ($t = 19$ h, $T = 30$ $^{\circ}\text{C}$) (mean \pm standard deviation, $n \geq 3$). The data for (Glc)Ent-Amx **6/8/10** and for the assays performed in the absence of DP are presented in Figs. S5-S9.

In the antibacterial activity assays described above, we treated the bacterial cultures with the apo conjugates and expect that the siderophore moieties chelate iron from the growth medium, allowing for recognition of the ferric-siderophore complexes by FepA and IronN. We previously reported that preloading of Ent-Amp/Amx with Fe(III) prior to antibacterial assays against *E. coli* K-12 had negligible effect on the MIC value.⁴⁴ Here we report that preloading of MGE-Amp/Amx

and DGE-Amp/Amx also has a negligible effect on the growth inhibitory properties (Fig. S10). This result is expected given that the concentration of iron in the growth medium far exceeds the MIC values obtained for the conjugates under conditions where FepA and IronN are expressed. Lastly, mixtures of unmodified Amp/Amx and (Glc)Ent **1-3** against *E. coli* CFT073 and UTI89 provide the same MIC values as Amp/Amx alone and confirm that the enhanced antibacterial activity of (Glc)Ent-Amp/Amx **5-10** requires the covalent attachment of β -lactams to the siderophore scaffolds (Figs. S11, S12).




Fig. 3. Time-kill kinetics of (Glc)Ent-Amp against *E. coli* CFT073 and UTI89. (a,b) Time-kill kinetics of (Glc)Ent-Amp **5/7/9** against (a) uropathogenic *E. coli* CFT073 ($\sim 10^8$ CFU/mL) treated with 50 μ M Amp or 5 μ M (Glc)Ent-Amp **5/7/9** and (b) uropathogenic *E. coli* UTI89 ($\sim 10^8$ CFU/mL) treated with 50 μ M Amp or 50 μ M (Glc)Ent-Amp **5/7/9**. All assays were performed in 50% MHB medium supplemented with 200 μ M DP (T = 37 °C) (mean \pm standard deviation, n \geq 3). The data for (Glc)Ent-Amx **6/8/10** and for the assays performed in the absence of DP are presented in Figs. S13-S14.

Siderophore Modification Accelerates Killing of Pathogenic *E. coli* CFT073. *E. coli* CFT073 is rapidly killed by conjugates **5-10** (Figs. 3a, S13). The OD₆₀₀ value of *E. coli* CFT073 culture (10⁸ CFU/mL) treated with 5 μM (Glc)Ent-β-lactam is reduced to almost the baseline value (≈0.04) after 1 h, which corresponds to a ≈2-fold log reduction in CFU/mL, whereas the change in OD₆₀₀ and CFU/mL for *E. coli* CFT073 treated with 50 μM Amp/Amx is negligible over this time period. In contrast, siderophore modification has negligible effect on the time-kill kinetics observed for *E. coli* UTI89 (Figs. 3b, S14); the (Glc)Ent-β-lactam conjugates provide similar profiles as observed for Amp/Amx. This result is reminiscent of our prior observations for *E. coli* K-12 where attachment of Ent to Amp/Amx provided only a modest increase in the time-kill kinetics compared to the parent antibiotics.⁴⁴ The origin of this strain-dependence is unclear and warrants further investigation. Nevertheless, these data show that glucosylation of Ent-Amp/Amx does not alter the time-kill kinetics of Ent-Amp/Amx for either *E. coli* CFT073 or UTI89, and (Glc)Ent-Amp/Amx **5-10** kill CFT073 more rapidly than UTI89.

Siderophore Competition Supports Recognition of (Glc)Ent-β-lactam Conjugates by IronN. To investigate interaction between (Glc)Ent-β-lactam conjugates **5-10** and the siderophore receptors FepA and IronN of *E. coli* CFT073 and UTI89, we performed modified antimicrobial activity assays where varying concentrations (0-10 μM) of (Glc)Ent **1-3** were combined with 100 nM (Glc)Ent-Amp/Amx **5-10** (Figs. 4, S15). These mixtures provide a means to probe competition between exogenous native siderophores and the conjugates for receptor recognition because siderophore uptake of the former molecules results in growth promotion whereas the latter afford growth inhibition. The competition assays establish that Ent and MGE attenuate the antibacterial activity of all (Glc)Ent-β-lactam conjugates **5-10** to varying degrees, whereas DGE only inhibits the activity of the glucosylated congeners **7-10**. Moreover, DGE fully attenuates DGE-Amp/Amx **9-10** but not MGE-Amp/Amx **7-8**. These conclusions are drawn from the following observations: (i) a 100-fold molar excess of Ent recovers the growth of *E. coli* CFT073 treated with Ent/MGE-Amp/Amx **5-8** to levels comparable to that of the untreated control (Figs. 4a, S15a). In contrast, a 100-fold excess of Ent provides only partial growth




Fig. 4. Exogenous (Glc)Ent compete with (Glc)Ent-Amp conjugates for FepA and IronN recognition. (a)-(c) Growth of *E. coli* CFT073 in the presence of 100 nM (Glc)Ent-Amp **5/7/9** and mixtures of 100 nM (Glc)Ent-Amp **5/7/9** and 1, 5, 20, or 100 equiv of exogenous (a) Ent **1**, (b) MGE **2**, or (c) DGE **3** in the presence of 200 μ M DP. (d)-(f) Growth of *E. coli* UTI89 in the presence of 100 nM (Glc)Ent-Amp **5/7/9** and mixtures of 100 nM (Glc)Ent-Amp **5/7/9** and 1, 5, 20, or 100 equiv of exogenous (d) Ent **1**, (e) MGE **2**, or (f) DGE **3** in the presence of 200 μ M DP. All assays were performed in 50% MHB medium ($t = 19$ h, $T = 30$ $^{\circ}$ C) (mean \pm standard deviation, $n = 3$). An asterisk indicates $OD_{600} < 0.01$. The data for (Glc)Ent-Amx **6/8/10** are presented in Fig. S15.

recovery of *E. coli* CFT073 treated with DGE-Amp/Amx **9-10**. (ii) A 100-fold excess of MGE fully recovers the growth of *E. coli* CFT073 treated with (Glc)Ent-Amp/Amx **5-10** (Figs. 4b, S15b). (iii) An 100-fold molar excess of DGE does not recover the growth of *E. coli* CFT073 treated with Ent-Amp/Amx **5-6**, whereas it provides partial and complete growth recovery of *E. coli* CFT073 treated with MGE-Amp/Amx **7-8** and DGE-Amp/Amx **9-10**, respectively (Figs. 4c, S15c). In total,

this work indicates that FepA recognises and delivers Ent/MGE-Amp/Amx **5-8** but not DGE-Amp/Amx **9-10**, whereas IroN binds and transports all conjugates based on three siderophore scaffolds. Competition assays employing *E. coli* UTI89 afford overall trends that are similar to those observed for *E. coli* CFT073 except that lower concentrations of exogenous siderophores effectively block the antibacterial action of (Glc)Ent-Amp (Figs. 4d-f, S15d-f).




Fig. 5. MGE/DGE-Amp selectively kill uropathogenic *E. coli* in the presence of non-pathogenic *E. coli* K-12 and the probiotic *L. rhamnosus* GG. (a,b) Bacterial growth monitored by (a) OD₆₀₀ and (b) CFU/mL for cultures of *E. coli* K-12 only, CFT073 only, and 1:1 K-12/CFT073 mixtures treated with 100 nM Amp or 100 nM (Glc)Ent-Amp **5/7/9** in the presence of 200 μM DP. (c,d) Bacterial growth monitored by (c) OD₆₀₀ and (d) CFU/mL for cultures of *E. coli* K-12 only, UTI89 only, and 1:1 K-12/UTI89 mixtures treated with 100 nM Amp or 100 nM (Glc)Ent-Amp **5/7/9** in the presence of 200 μM DP. (e,f) Bacterial growth monitored by (e) OD₆₀₀ and (f) CFU/mL for cultures of *L. rhamnosus* GG only, *E. coli* CFT073 only, and 1:1 *L. rhamnosus* GG/*E. coli* CFT073 mixtures treated with 1 μM Amp or 1 μM (Glc)Ent-Amp **5/7/9** in the presence of 200 μM DP. All mixed-*E. coli* antimicrobial assays were performed in 50% MHB medium and all mixed-species antimicrobial assays were conducted in 1:1 MRS:MHB medium (t = 19 h, T = 30 °C) (mean ± standard deviation, n = 3). An asterisk indicates OD₆₀₀ < 0.01 or no colony formation. The data for (Glc)Ent-Amx **6/8/10** are presented in Fig. S16.

GlcEnt-Amp/Amx Kill Pathogenic *E. coli* in the Presence of Other Microbes that Include Non-Pathogenic *E. coli* and Commensal Lactobacilli. To further probe the activity spectrum and investigate strain selectivity of GlcEnt-Amp/Amx, we performed mixed-species assays to determine whether these conjugates will selectively kill pathogenic *E. coli* that express IroN cultured in the presence of other organisms. These assays confirmed that GlcEnt-Amp/Amx **7-10** selectively kill pathogenic *E. coli* that express IroN in the presence of *E. coli* strains that do not express this receptor. Treatment of co-cultures of pathogenic *E. coli* (CFT073 or UTI89, transformed with the chloramphenicol resistance plasmid pSG398) and non-pathogenic *E. coli* K-12 (transformed with the kanamycin resistance plasmid pET29a) with 100 nM Ent-Amp/Amx **5-6** results in complete killing of both strains (Figs. 5a-d, S16a-d). In contrast, treatment of the co-cultures with 100 nM GlcEnt-Amp/Amx **7-10** affords killing of the uropathogenic *E. coli* concomitant with *E. coli* K-12 survival (Figs. 5a-d, S16a-d). Taken together, these results demonstrate that GlcEnt- β -lactam conjugates **7-10** provide strain-specific targeting of the antibacterial cargo to virulent *E. coli* that express IroN.

(Glc)Ent-Amp/Amx **5-10** also target pathogenic *E. coli* in the presence of commensal microbes. Lactobacilli are Gram-positive commensal bacteria of the human gastrointestinal tract, and are also found in the urinary and genital tracts.⁶¹ Some Lactobacilli reduce recurrent urinary tract infections in women.⁶² Lactobacilli have little-to-no minimal metabolic iron requirement, and do not employ enterobactin or salmochelins for iron acquisition.^{63,64} *Lactobacillus rhamnosus* GG (ATCC 53103), a human commensal that is considered to be a probiotic, is susceptible to β -lactam antibiotics, and we obtained a MIC value of 10 μ M for Amp/Amx against this strain (1:1 MRS:MHB medium, \pm DP) (Fig. S17). In contrast, 10 μ M (Glc)Ent-Amp/Amx **5-10** have negligible effect on *L. rhamnosus* GG growth (Fig. S17). Treatment of *E. coli* CFT073 and *L. rhamnosus* GG co-cultures with (Glc)Ent-Amp/Amx **5-10** affords selective killing of *E. coli* CFT073 (Figs. 5e,f, S16e,f).

We previously reported that modification of Amp/Amx with Ent attenuated the activity of the β -lactam against *Staphylococcus aureus* ATCC 25923.⁴⁴ In the current work we obtained a

similar result with GlcEnt-Amp/Amx, and found that the salmochelin modification lowers the antibacterial activity of Amp/Amx against *S. aureus* by 10-fold (Fig. S18). Moreover, treatment of *E. coli* CFT073 and *S. aureus* co-cultures with DGE-Amp/Amx **9,10** affords selective killing of *E. coli* CFT073 (Figs. S19a,b, S20a,b). Selective killing of *E. coli* CFT073 co-cultured with *Acinetobacter baumannii* ATCC 17961 also occurred (Figs. S19c,d, S20c,d, S21). Substitution of *E. coli* CFT073 with UTI89 in these assays afforded similar selectivity trends (Figs. S22, S23). In total, the mixed-species assays provide support for DGE-based targeting of the antibacterial cargo to IroN-expressing strains.

GlcEnt-Amp/Amx Kill *E. coli* in the Presence of Lipocalin-2. To ascertain whether GlcEnt-Amp/Amx **7-10** overcome Lcn2 sequestration, in analogy to Lcn2 evasion by the salmochelins,^{14,19} we conducted antibacterial assays with *E. coli* CFT073 in the absence or presence of Lcn2 or bovine serum albumin (BSA, control). These assays were conducted in modified M9 medium,⁶⁵ and 100 nM (Glc)Ent-Amp/Amx **5-10** provide complete growth inhibition of *E. coli* CFT073 in this medium (Fig. 6). A 10-fold excess of Lcn2 attenuates the antibacterial activity of Ent-Amp/Amx **5-6**, in agreement with prior work.⁴⁴ In contrast, Lcn2 has negligible effect on the antimicrobial activity of GlcEnt-Amp/Amx **7-10** against *E. coli* CFT073 (Figs. 6, S24).




Fig. 6. Antibacterial activity of (Glc)Ent-Amp/Amx against *E. coli* CFT073 in the presence of Lcn2 or bovine serum albumin (BSA). *E. coli* CFT073 was treated with (a) 100 nM (Glc)Ent-Amp **5/7/9** or (b) 100 nM (Glc)Ent-Amx **6/8/10** in the absence (control) and presence of 1 μ M Lcn2 or 1 μ M BSA. The assays were conducted in modified M9 medium ($t = 24$ h, $T = 37$ °C) (mean \pm standard deviation, $n = 3$). An asterisk indicates $OD_{600} < 0.01$. The data for the conjugates preloaded with Fe(III) are presented in Fig. S24.

GlcEnt-Amp/Amx Exhibit Low Cytotoxicity to Human T84 Cells. The cytotoxicity of apo- and iron-bound GlcEnt-Amp/Amx **7-10** (≤ 10 μ M) against human T84 colon epithelial cells was evaluated by the MTT assay. In all cases, the cell viability was $\geq 80\%$ of that of the untreated control, indicating that the conjugates exhibit negligible cytotoxicity to T84 cells over a 24-h period (Fig. S25).

Conclusions

In this work, inspired by the siderophore recognition strategies utilised by *E. coli* for iron acquisition in the host, we report a siderophore-based approach for antibiotic delivery that targets strains that express IroN, a siderophore receptor that contributes to virulence. First, we establish that the tailoring enzymes IroB and MceC can C-glucosylate monofunctionalized Ent and therefore be employed in chemoenzymatic synthesis to afford functionalized salmochelins. Next, we demonstrate that GlcEnt- β -lactam conjugates are recognised by siderophore transport machinery, target IroN, provide ≥ 100 -fold enhanced antibacterial activity against uropathogenic *E. coli* relative to the parent β -lactams, afford killing of virulent *E. coli* in the presence of non-pathogenic *E. coli* and other commensal strains, and overcome the enterobactin-sequestering host-defense protein Lcn2. Our results establish that conjugation of a broad-spectrum antibiotic to a siderophore tunes the activity profile of the parent antibiotic. With the appropriate choice of siderophore, the antibacterial activity spectrum can be modulated to afford species- and strain-specific targeting. In broad terms, targeting pathogens is important for pharmaceutical development, which will ultimately afford treatment options that minimally perturb the commensal microbiota.^{66,67}

IroN was first discovered in *Salmonella*¹⁸ and subsequently identified in other Enterobacteriaceae. Our current work focuses on antibiotic delivery to uropathogenic *E. coli* that harbour the *iroA* gene cluster, and we expect that this strategy will be applicable to other pathogens that employ salmochelins for iron acquisition. At present, 121 completely sequenced *E. coli* genomes are available, which include 46 human pathogens. A BLAST search using *iroN* from *E. coli* CFT073 afforded hits with $\geq 99\%$ sequence identity for three uropathogenic *E. coli* (UTI89, 536, and 83792), adherent invasive *E. coli* UM146, the meningitis isolate *E. coli* IHE3034, and a carbapenemase-producing isolate *E. coli* ECONIH1 (Table S4). The probiotic *E. coli* Nissle 1917 and the laboratory reference strain for antimicrobial testing *E. coli* ATCC 25922 were the only other *E. coli* revealed as hits. Studies of the distribution of siderophore biosynthetic machinery in *E. coli* isolated from feces of healthy mammals indicate that $\approx 20\%$ of

the commensal isolates produce salmochelins.⁶⁸ This observation suggests that one potential limitation of GlcEnt-based antibiotic delivery is that a fraction of commensal *E. coli* harbour the *iroA* cluster are susceptible and, conversely, that some pathogenic *E. coli* do not. Regarding the former possibility, the healthy gut is considered to be a reservoir for *E. coli* that cause infections of the urinary tract,^{58,69-71} and the ability to target such pathobionts using siderophores may be advantageous in certain cases. In addition to *Salmonella* and *E. coli*, BLAST revealed that the genomes of the human pathogens *Shigella dysenteriae* 1617 and Sd197, *Enterobacter cloacae*, *Klebsiella pneumoniae*, and *Enterobacter aerogenes* encode *iroN* (Table S4). Thus, it will be informative to determine whether DGE also provides targeted antibiotic delivery to these problematic strains.

Our current investigations also provide fundamental insights into siderophore recognition and transport. Prior studies of siderophore uptake in *Salmonella* revealed that both FepA and IroN recognize and transport Ent.⁷² Our competition assays employing uropathogenic *E. coli* are in agreement with this observation, and indicate that both receptors deliver Ent-Amp/Amx **5-6** into *E. coli*. Moreover, our competition data suggest that MGE **2** and MGE-Amp/Amx **7-8** are recognised and transported by FepA as well as IroN of *E. coli*. In contrast, DGE **3** only competes with GlcEnt-Amp/Amx **7-10** and most effectively blocks the activity of DGE-Amp/Amx **9-10**. These observations support exclusive transport of DGE-Amp/Amx **9-10** through IroN. Indeed, prior studies demonstrated that IroN is required for transporting salmochelin extracts isolated from several *S. enterica* strains,¹⁶ and *in vitro* activity assays reveal that IroB accumulates DGE **3**.⁵¹

We previously reported that *E. coli* CFT073 exhibits greater sensitivity to Ent-Amp/Amx **5-6** than *E. coli* UTI89,⁴⁴ and we observe the same trend with GlcEnt-Amp/Amx **7-10**. The physiological origins of this observation remain unclear. One possible explanation may be differences in the siderophore biosynthetic and uptake machineries employed by these two uropathogens. *E. coli* CFT073 expresses a third catecholate siderophore receptor, Iha,⁷³ whereas *E. coli* UTI89 biosynthesizes yersiniabactin, a siderophore mainly used by *Yersinia*

spp.⁷⁴ Alternatively, as-yet unidentified factors may account for these trends, and further studies are warranted to understand these observations.

In closing, this investigation establishes that siderophores and the siderophore uptake machinery employed by virulent bacteria provide a powerful approach for targeting pathogenesis in the context of antibacterial drug discovery. Narrow-spectrum and species-specific antibiotics are needed for treating infections where the causative agent is known and, when coupled with rapid diagnostics, will ultimately reduce the onset of secondary infections and evolution of antibiotic resistance.^{2,5,7} The current study focuses on targeting broad-spectrum β -lactam antibiotics to pathogenic *E. coli* on the basis of iron acquisition machinery that is employed by these pathogens during colonisation in the host. We establish that native salmochelins can be used as scaffolds for “Trojan horse” antibiotic delivery to hijack the iron acquisition machinery that contributes to pathogenicity. It will be important to ascertain whether this salmochelin-inspired strategy is applicable to other Gram-negatives, such as *Salmonella* and *K. pneumoniae*, which cause human disease and utilise salmochelins for iron acquisition. Leveraging this strategy to target other antibacterial cargos and thereby modulate activity and mitigate off-target effects is another important avenue of future chemical and biological investigation.

Experimental Section

Synthetic Reagents. Anhydrous dimethyl sulfoxide (DMSO) was purchased from Sigma-Aldrich and used as received. All other chemicals and solvents were purchased from Sigma-Aldrich or Alfa Aesar in the highest available purity and used as received. The syntheses of Ent **1**,⁷⁵ MGE **2**,⁵² DGE **3**,⁵¹ Ent-Amp **5**, Ent-Amx **6**, Ent-PEG₃-N₃ **11**, Amp-alkyne **14**, Amx-alkyne **15**, are reported elsewhere.⁴⁴

Instrumentation. Analytical and semi-preparative high-performance liquid chromatography (HPLC) were performed using an Agilent 1200 series HPLC system outfitted

with a Cliepus reverse-phase C18 column (5- μ m pore size, 4.6 x 250 mm; Higgins Analytical, Inc.) at a flow rate of 1 mL/min and an Agilent Zorbax reverse-phase C18 column (5- μ m pore size, 9.4 x 250 mm) at a flow rate of 4 mL/min, respectively. The multi-wavelength detector was set to read the absorbance at 220, 280, and 316 (catecholates absorption) nm. HPLC-grade acetonitrile (MeCN) and trifluoroacetic acid (TFA) were purchased from EMD and Alfa Aesar, respectively. For HPLC analyses, solvent A was 0.1% TFA/H₂O and solvent B was 0.1% TFA/MeCN, unless stated otherwise. The HPLC solvents were prepared with HPLC-grade MeCN and TFA, and Milli-Q water (18.2 m Ω •cm), and filtered through a 0.2- μ m filter before use. For analytical HPLC to evaluate conjugate purity, the entire portion of each HPLC-purified compound was dissolved in a mixture of 1:1 MeCN/H₂O and an aliquot was taken for HPLC analysis. The remaining solution was subsequently lyophilized.

High-resolution mass spectrometry was performed by using an Agilent LC-MS system comprised of an Agilent 1260 series LC system outfitted with an Agilent Poroshell 120 EC-C18 column (2.7- μ m pore size) and an Agilent 6230 TOF system housing an Agilent Jetstream ESI source. For all LC-MS analyses, solvent A was 0.1% formic acid/H₂O and solvent B was 0.1% formic acid/MeCN (LC-MS grade, Sigma-Aldrich). The samples were analysed using a solvent gradient of 5-95% B over 10 min with a flow rate of 0.4 mL/min. The MS profiles were analysed and deconvoluted by using Agilent Technologies Quantitative Analysis 2009 software version B.03.02.

Optical absorption spectra were recorded on an Beckman Coulter DU800 spectrophotometer (1-cm quartz cuvettes, Starna). A BioTek Synergy HT plate reader was used to record absorbance at 600 nm (OD₆₀₀) for antimicrobial activity assays and absorbance at 550 nm for cytotoxicity assays.

Enzymatic Activity Assays for IroB and MceC. The enzymes MceC and IroB were over-expressed as N-terminal His₆-fusion proteins in *E. coli* BL21 (DE3) and purified as reported.^{51,52} To a 405- μ L solution containing Ent-PEG₃-N₃ **11** (100 μ M), uridine diphosphoglucose (UDP-Glc, 3 mM), and MgCl₂ (5 mM) prepared in 75 mM Tris-HCl buffer, pH

8.0, MceC (10 μ M, 45 μ L) or IroB (10 μ M, 45 μ L) was added to afford a final enzyme concentration of 1 μ M. The reaction was incubated at room temperature and an aliquot (100 μ L) was quenched by adding 10 μ L of 6% TFA (aq) after 0, 15, 30, 60 min. The quenched reaction aliquots were immediately vortexed, centrifuged (13,000 rpm x 10 min, 4 $^{\circ}$ C), and analysed by HPLC (0-100% B over 30 min, 1 mL/min). The results are shown in Figs. S1, S2.

Synthesis of MGE/DGE-PEG₃-N₃ (12-13). A 6.3-mL solution containing Ent-PEG₃-N₃ **11** (500 μ M), uridine diphosphoglucose (UDP-Glc, 3 mM), and MgCl₂ (5 mM) was prepared in 75 mM Tris-HCl buffer, pH 8.0 and divided into seven 900- μ L aliquots. MceC (50 μ M, 100 μ L) or IroB (50 μ M, 100 μ L) was added to each aliquot to afford a final enzyme concentration of 5 μ M. The 1-mL reactions were incubated at room temperature and quenched by addition of 100 μ L of 6% TFA (aq) after 15 min (MceC reaction) or 2 h (IroB reaction). The quenched reaction aliquots were immediately vortexed, combined, and lyophilized to dryness. The resulting powder was dissolved in 3 mL of 1:1 MeCN/water and centrifuged (13,000 rpm x 10 min, 4 $^{\circ}$ C). MGE-PEG₃-N₃ **12** and DGE-PEG₃-N₃ **13** were purified from the supernatant of MceC- and IroB-catalysed reaction, respectively, by using semi-preparative HPLC (20-45% B over 8.5 min, 4 mL/min). Both compounds were obtained as white powders (MGE-PEG₃-N₃ **12**, 0.66 mg, 41% from MceC-catalyzed reaction; DGE-PEG₃-N₃ **13**, 0.85 mg, 45% from IroB-catalysed reaction). HRMS (ESI): MGE-PEG₃-N₃ **12**, [M+H]⁺ *m/z* calcd. 1076.3215, found 1076.3214; DGE-PEG₃-N₃ **13**, [M+H]⁺ *m/z* calcd. 1238.3743, found 1238.3744. The analytical HPLC traces of the purified compounds are reported Figs. S26, S27.

Synthesis of MGE-Amp (7). Amp-alkyne **14** (50 μ L of a 50-mM solution in DMSO, 2.5 μ mol) and MGE-PEG₃-N₃ **12** (73 μ L of an 11.3-mM solution in DMSO, 0.825 μ mol) were combined and 100 μ L of DMSO was added. A aliquot of aqueous CuSO₄ (50 μ L of a 90-mM solution in water, 4.5 μ mol) and tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA, 100 μ L of a 50-mM solution in DMSO, 5 μ mol) were combined to give a blue-green solution, to which sodium ascorbate (NaAsc, 100 μ L of a 180-mM solution in water, 18.0 μ mol) was added. This solution became light yellow and was immediately added to the alkyne/azide solution. The

reaction was gently mixed on a bench-top rotator for 2 h at room temperature and conjugate **7** was purified by semi-preparative HPLC (20% B for 5 min and 20%-50% B over 11 min, 4 mL/min; 0.005% TFA was used in solvents A and B because of the acid-sensitive β -lactam moiety). Conjugate **7** was obtained as white powder (0.75 mg, 59%). HRMS (ESI): $[M+H]^+$ m/z calcd., 1519.4730; found, 1519.4639. The analytical HPLC trace of the purified product is reported in Fig. S28.

Synthesis of MGE-Amx (8). As described for MGE-Amp with the exception that Amx-alkyne **15** was used instead of Amp-alkyne **14**. Conjugate **8** was purified by semi-preparative HPLC (20% B for 5 min and 20%-42% B over 11 min, 4 mL/min) and obtained as white powder (0.49 mg, 31%). HRMS (ESI): $[M+H]^+$ m/z calcd., 1535.4679; found, 1535.4685. The analytical HPLC trace of the purified product is reported in Fig. S29.

Synthesis of DGE-Amp (9). As described for MGE-Amp with the exception that DGE-PEG₃-N₃ **13** was used instead of MGE-PEG₃-N₃ **12**. Conjugate **9** was purified by semi-preparative HPLC (0% B for 5 min and 0%-50% B over 13 min, 4 mL/min) and obtained as white powder (0.67 mg, 48%). HRMS (ESI): $[M+Na]^+$ m/z calcd., 1703.5077; found, 1703.5069. The analytical HPLC trace of the purified product is reported in Fig. S30.

Synthesis of DGE-Amx (10). As described for MGE-Amp with the exception that Amx-alkyne **15** and DGE-PEG₃-N₃ **13** were used instead of Amp-alkyne **14** and MGE-PEG₃-N₃ **12**. Conjugate **10** was purified by semi-preparative HPLC (0% B for 5 min and 0%-50% B over 13 min, 4 mL/min) and obtained as white powder (0.36 mg, 26%). HRMS (ESI): $[M+H]^+$ m/z calcd., 1697.5207; found, 1697.5235. The analytical HPLC trace of the purified product is reported in Fig. S31.

Storage and Handling of Siderophores and Siderophore-Antibiotic Conjugates. All (Glc)Ent **1-3** and siderophore-antibiotic conjugates **5-10** were stored as DMSO stock solutions at -20 °C. The stock solution concentrations for (Glc)Ent-Amp/Amx **5-10** ranged from 2 to 5 mM. These values were determined by diluting the DMSO stock solution in MeOH and using the reported extinction coefficient for enterobactin in MeOH (316 nm, 9,500 M⁻¹cm⁻¹).⁷⁶ To minimize

multiple freeze-thaw cycles, the resulting solutions were divided into 50- μ L aliquots and stored at -20 °C. The β -lactam moieties and enterobactin trilactone are susceptible to hydrolysis, and aliquots were routinely analyzed by HPLC to confirm the integrity of the samples.

General Microbiology Materials and Methods. Information pertaining to all bacterial strains used in this study is listed in Table S1. Freezer stocks of all *Escherichia coli* strains (*E. coli* K-12, B, H9049, CFT073, and UTI89), *Staphylococcus aureus* ATCC 25923, and *Acinetobacter baumannii* ATCC 17961 were prepared from single colonies in 25% glycerol/Luria Broth (LB) medium. Freezer stocks of *Lactobacillus rhamnosus* GG ATCC 53103 were prepared from single colonies in 25% glycerol/de Man, Rogosa, and Sharpe (MRS) medium.

LB, MRS, 5x M9 minimal medium and agar were purchased from BD. Mueller Hinton Broth (MHB) was purchased from Fluka. Recombinant human Lcn2 was purchased from R&D System (Minneapolis, MN). The iron chelator 2,2'-dipyridyl (DP) was purchased from Sigma-Aldrich. All growth medium and Milli-Q water used for bacterial cultures or for preparing solutions of the enterobactin-antibiotic conjugates were sterilized by using an autoclave. A DP stock solution (200 mM) was prepared in DMSO and used in the bacteria growth assays requiring iron-depleted conditions. Working dilutions of the siderophore and siderophore-antibiotic conjugate stock solutions were prepared in 10% DMSO/H₂O. For all assays, the final cultures contained 1% v/v DMSO. Sterile polypropylene culture tubes and sterile polystyrene 96-well plates used for culturing were purchased from VWR and Corning Incorporated, respectively. The optical density at 600 nm (OD₆₀₀) was recorded on a Beckman Coulter DU800 spectrophotometer or by using a BioTek Synergy HT plate reader.

Growth Studies of *E. coli* in the Presence of DP. Overnight cultures of *E. coli* were prepared by inoculating 5 mL of Luria Broth (LB) medium with bacterial freezer stocks. The cultures were incubated at 37 °C in a tabletop incubator with shaking at 150 rpm for 16-18 h. The overnight culture was diluted 1:100 into 5 mL of fresh LB medium containing DP (200 μ M) and incubated at 37 °C with shaking at 150 rpm until OD₆₀₀ reached 0.6. The cultures were subsequently diluted to an OD₆₀₀ value of 0.001 using 50% MHB medium (11.5 g/L). A 90- μ L

aliquot of the diluted culture was combined with a 10- μ L aliquot of a 10x solution of DP (0, 0.25, 0.5, 1, 2, 4, and 8 mM) in a 96-well plate, which was wrapped in Parafilm and incubated at 30 °C with shaking at 150 rpm. Bacterial growth was determined at $t = 0, 2, 4, 6, 8, 10,$ and 20 h by measuring the OD₆₀₀ using a BioTek Synergy HT plate reader. Each well condition was prepared in duplicate and at least three independent replicates were conducted on different days and using different synthetic batches of each conjugate. The resulting mean OD₆₀₀ values are reported and the error bars represent the standard deviation.

General Procedure for Antimicrobial Activity Assays. Overnight cultures of *E. coli*, *S. aureus*, and *A. baumannii* were prepared by inoculating 5 mL of Luria Broth (LB) medium with bacterial freezer stocks. The cultures were incubated at 37 °C in a tabletop incubator with shaking at 150 rpm for 16-18 h. The overnight culture was diluted 1:100 into 5 mL of fresh LB medium containing DP (200 μ M) and incubated at 37 °C with shaking at 150 rpm until OD₆₀₀ reached 0.6. The cultures were subsequently diluted to an OD₆₀₀ value of 0.001 using 50% MHB medium (11.5 g/L) with or without DP (200 μ M). A 90- μ L aliquot of the diluted culture was combined with a 10- μ L aliquot of a 10x solution of Amp/Amx or (Glc)Ent-Amp/Amx **5-10** in a 96-well plate, which was wrapped in Parafilm and incubated at 30 °C with shaking at 150 rpm for 19 h. Bacterial growth was determined by measuring the OD₆₀₀ using a BioTek Synergy HT plate reader. Each well condition was prepared in duplicate and at least three independent replicates were conducted on different days and using different synthetic batches of each conjugate. The resulting mean OD₆₀₀ values are reported and the error bars represent the standard deviation.

For *L. rhamnosus* GG ATCC 53103, the bacteria culture was grown in MRS medium overnight. The resulting culture was diluted 1:50 into 5 mL of fresh MRS medium containing DP (200 μ M) and incubated at 37 °C with shaking at 150 rpm until OD₆₀₀ reached 1.0. The culture was subsequently diluted to an OD₆₀₀ value of 0.004 in 1:1 MRS:MHB medium with or without DP (200 μ M). The antibacterial activity assays were performed as described above for *E. coli*.

Time-Kill Kinetic Assays. A 5-mL overnight culture of *E. coli* CFT073 or UTI89 grown

in LB medium was diluted 1:100 into 5 mL of fresh LB medium with 200 μ M DP and incubated at 37 °C with shaking at 150 rpm until OD₆₀₀ reached \approx 0.3. The culture was centrifuged (3000 rpm x 10 min, rt) and the resulting pellet was resuspended in 50% MHB and centrifuged (3000 rpm x 10 min, rt). The resulting pellet was resuspended in 50% MHB with or without DP (200 μ M) and the OD₆₀₀ was adjusted to 0.3. A 90- μ L aliquot of the resulting culture was combined with a 10- μ L aliquot of a 10x solution of Amp/Amx or (Glc)Ent-Amp/Amx **5-10** in a 96-well plate, which was wrapped in Parafilm and incubated at 37 °C with shaking at 150 rpm. The OD₆₀₀ values were recorded at t = 0, 1, 2, and 3 h. In a parallel experiment, a 10- μ L aliquot of the culture was taken at t = 0, 1, 2, and 3 h and serially diluted by using sterile phosphate-buffered saline (PBS) and plated on LB agar to obtain colony forming units (CFU/mL). Each well condition was repeated at least three times independently on different days. The resulting mean OD₆₀₀ or CFU/mL is reported and the error bars are the standard deviation.

Antimicrobial Activity Assays in the Presence of Unmodified (Glc)Ent. These assays were performed following the general procedure (Supplementary Information) except that varying concentrations of Ent, MGE, or DGE were mixed with Ent-Amp/Amx **5-6**, MGE-Amp/Amx **7-8**, or DGE-Amp/Amx **9-10**. Ent was synthesized following a literature procedure,⁷⁵ MGE **2** and DGE **3** were prepared from Ent using MceC and IroB as described for MGE-PEG₃-N₃ **12** and DGE-PEG₃-N₃ **13**. Stock solutions of (Glc)Ent **1-3** were prepared in DMSO and stored at -20 °C.

Mixed-*E. coli* Assays. The pET29a plasmid (kanamycin resistance) was transformed into *E. coli* K-12, and the pHSG398 plasmid (chloramphenicol resistance) was transformed into *E. coli* CFT073 and UTI89, via electroporation. Overnight cultures of the bacterial strains were prepared by inoculating 5 mL of LB medium containing the appropriate antibiotic (kanamycin, 50 μ g/mL; chloramphenicol, 34 μ g/mL) with bacterial freezer stocks, and the cultures were incubated at 37 °C in a tabletop incubator shaker set at 150 rpm for 16-18 h. Each overnight culture was diluted 1:100 into 5 mL of fresh LB medium containing 200 μ M DP, but no antibiotics, and incubated at 37 °C with shaking at 150 rpm until OD₆₀₀ reached 0.6. The

cultures were diluted to an OD₆₀₀ value of 0.001 in 50% MHB separately or in a 1:1 mixture (10⁶ CFU/mL for each strain), with or without 200 μM DP. No antibiotic marker was included in these cultures. Aliquots of these cultures were serially diluted by using sterile PBS and plated on LB agar plates with or without corresponding antibiotic to confirm the CFU of the starter cultures. A 90-μL aliquot of each culture was combined with a 10-μL aliquot of a 1-μM solution of Amp/Amx or (Glc)Ent-Amp/Amx **5-10** in a 96-well plate. The plate was then wrapped in Parafilm and incubated at 30 °C with shaking at 150 rpm for 19 h. Bacterial growth was evaluated by measuring OD₆₀₀ as well as counting colonies formed on LB agar with or without kanamycin/chloramphenicol after serial dilution with sterile PBS. Each well condition was repeated at least three times independently on different days. The resulting mean OD₆₀₀ and CFU/mL values are reported and the error bars are the standard deviation.

Mixed-species Assays. These assays were performed following the mixed-*E. coli* assay procedure except that *E. coli* CFT073 and *L. rhamnosus* GG ATCC 53103 were used. A 5-mL culture of *E. coli* CFT073 or *L. rhamnosus* GG was grown for 16-18 h in LB or MRS medium, respectively. The overnight culture was diluted 1:100 (*E. coli*) or 1:50 (*L. rhamnosus* GG) into 5 mL of fresh LB or MRS medium with 200 μM DP and incubated at 37 °C with shaking at 150 rpm until OD₆₀₀ reached 0.6 (*E. coli*) or 1.0 (*L. rhamnosus* GG). The cultures were diluted to an OD₆₀₀ value of 0.001 (*E. coli*) or 0.004 (*L. rhamnosus* GG) in 1:1 MRS:MHB containing 200 μM DP separately or in a 1:1 mixture (10⁶ CFU/mL for each strain). Aliquots of these cultures were serially diluted by using sterile PBS and plated on LB and MRS agar plates to confirm the CFU of the starter culture. A 90-μL aliquot of each culture was combined with a 10-μL aliquot of a 10-μM solution of Amp/Amx or (Glc)Ent-Amp/Amx **5-10** in a 96-well plate, which was wrapped in Parafilm and incubated at 30 °C with shaking at 150 rpm for 19 h. Bacterial growth was assayed by both measuring OD₆₀₀ and counting colonies formed on LB and MRS agar plates after serial dilution with sterile PBS. Each well condition was repeated at least three times independently on different days. The resulting mean OD₆₀₀ and CFU/mL values are reported and the error bars are the standard deviation. Comment: *E. coli* CFT073 forms

colonies more quickly than *L. rhamnosus* GG on LB agar plates, whereas *L. rhamnosus* GG colonies appear more quickly than those of *E. coli* CFT073 on MRS agar plates, and these behaviors allow for each strain to be monitored independently over a 24-h period.

The assays were also performed by co-culturing *E. coli* CFT073 or UTI89 with *S. aureus* ATCC 25923 or *A. baumannii* ATCC 17961. A 5-mL culture of each individual bacterial strain was grown for 16-18 h in LB. The overnight culture was diluted 1:100 into 5 mL of fresh LB with 200 μ M DP and incubated at 37 °C with shaking at 150 rpm until OD₆₀₀ reached 0.6. The cultures were diluted to an OD₆₀₀ value of 0.001 in 50% MHB containing 200 μ M DP separately or in a 1:1 mixture (10⁶ CFU/mL for each strain). A 90- μ L aliquot of each culture was combined with a 10- μ L aliquot of a 10- μ M solution of Amp/Amx or (Glc)Ent-Amp/Amx **5-10** in a 96-well plate, which was wrapped in Parafilm and incubated at 30 °C with shaking at 150 rpm for 19 h. Bacterial growth was assayed by both measuring OD₆₀₀ and counting colonies formed on HardyCHROM UTI plates after serial dilution with sterile PBS. Plating *E. coli* strains on these plates results in pink colonies, whereas *S. aureus* and *A. baumannii* provide white colonies. Each well condition was repeated at least three times independently on different days. The resulting mean OD₆₀₀ and CFU/mL values are reported and the error bars are the standard deviation.

Antimicrobial Activity Assays in the Presence of Lipocalin 2. Cultures of *E. coli* CFT073 were grown in modified M9 minimal medium⁶⁵ (Na₂HPO₄ 6.8 g/L, KH₂PO₄ 3 g/L, NaCl 0.5 g/L, NH₄Cl 1 g/L, 0.4% glucose, 2 mM MgSO₄, 0.1 mM CaCl₂, 0.2% casein amino acids, and 16.5 μ g/mL of thiamine) for 16-18 h. The overnight culture grew to saturation and was diluted 1:100 into 5 mL of fresh modified M9 minimal medium and incubated at 37 °C with shaking at 150 rpm until OD₆₀₀ reached 0.6. The OD₆₀₀ of the culture was adjusted to 0.001, and the culture was further diluted 1:100 with the M9 medium in two steps (1:10 x 1:10). The corresponding CFU was determined to be $\sim 10^4$ CFU/mL by plating on LB agar plates. Lipocalin 2 (Lcn2, R&D Systems) was diluted into PBS buffer to a concentration of 20 μ M and frozen at -20 °C until use. Bovine serum albumin (BSA, Sigma-Aldrich) was prepared in PBS buffer to achieve a

concentration of 20 μM . A 90- μL aliquot of the diluted culture was combined with a 5- μL aliquot of a 20x solution of (Glc)Ent-Amp/Amx **5-10** and a 5- μL aliquot of Lcn2 or BSA in a 96-well plate, which was wrapped in Parafilm and incubated at 37 $^{\circ}\text{C}$ with shaking at 150 rpm for 24 h. Bacterial growth was determined by OD_{600} . Each well condition was repeated at least three times independently on different days. The resulting mean OD_{600} is reported and the error bars are the standard deviation.

Cytotoxicity Assays. The human colon epithelial T84 cell line was purchased from ATCC and cultured in 1:1 DMEM/F12 medium with 10% fetal bovine serum, and 1% penicillin and streptomycin (v/v, ATCC). The cells were grown to approximately 95% confluency and treated with 3 mL of trypsin-EDTA (Corning). A 12-mL portion of fresh medium was added to the detached cells, and the T84 cell suspension was centrifuged (600 rpm \times 5 min, 37 $^{\circ}\text{C}$). The supernatant was discarded and the cell pellet was resuspended in 6 mL of the fresh culture medium. The concentration of cells was quantified by using a manual hemocytometer (VWR International) and adjusted to 1×10^5 cells/mL. A 90- μL aliquot of T84 cells were then added to 96-well plates and incubated at 37 $^{\circ}\text{C}$ and 5% CO_2 for 24 h. Stock solutions (10x) of Amp/Amx or (Glc)Ent-Amp/Amx **5-10** were prepared in sterile-filtered 10% DMSO/ H_2O and 10 μL of each solution was added to the appropriate well. The plate was incubated at 37 $^{\circ}\text{C}$ and 5% CO_2 for another 24 h. 3-[4,5-Dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT, Alfa Aesar) was dissolved in sterile PBS and the concentration was adjusted to 5 mg/mL. The resulting yellow solution was filtered through a 0.2- μm filter and a 20- μL aliquot of the resulting MTT solution was added to each well. The plate was incubated at 37 $^{\circ}\text{C}$ and 5% CO_2 for 4 h and the supernatant was removed from each well. DMSO (100 μL) was added to each well and the absorbance at 550 nm was recorded by using a plate reader. Blank readings were recorded on wells that contained only the medium. The assay was repeated in triplicate on different days, and the mean and standard deviation are reported.

Acknowledgements

We gratefully acknowledge financial support from the Pacific Southwest Research Center of Excellence for Biodefense and Emerging Infectious Disease, the Searle Scholars Program (Kinship Foundation), the Department of Chemistry at MIT, and a Royal Thai Government Fellowship (P.C.). We thank Prof. Lynette Cegelski for providing *E. coli* UTI89 and Prof. Christopher T. Walsh for providing *E. coli* H9049.

Competing financial interests

A patent application covering GlcEnt-Amp/Amx has been filed.

Supplementary Information

Tables of bacterial strains employed in this study, iron content of the antimicrobial activity medium, characterization of GlcEnt-Amp/Amx **7-10**, GlcEnt-PEG₃-N₃ **12-13**, and BLAST search for *iroN* sequence. Figures of HPLC traces of MceC- and IroB-catalyzed glucosylation of Ent-PEG₃-N₃ **11**, optical absorption spectra of GlcEnt-Amp/Amx **7-10**, additional antimicrobial activity assays, time-kill kinetics, competition assays for FepA and IroN recognition, mixed-species antimicrobial activity assays, Lcn2 effect on antibacterial activity of GlcEnt-Amp/Amx **7-10**, and cytotoxicity assays against T84 cells. This material is available free of charge via the Internet at <http://pubs.rsc.org>.

References

1. *Antimicrobial resistance: global report on surveillance 2014*, World Health Organization, Geneva, 2014.
2. *Report to the president on combating antibiotic resistance*, President's Council of Advisors on Science and Technology, 2014.
3. M. A. Fischbach and C. T. Walsh, *Science*, 2009, **325**, 1089-1093.

4. D. J. Payne, M. N. Gwynn, D. J. Holmes and D. L. Pompliano, *Nat. Rev. Drug Discov.*, 2007, **6**, 29-40.
5. A. E. Clatworthy, E. Pierson and D. T. Hung, *Nat. Chem. Biol.*, 2007, **3**, 541-548.
6. K. Lewis, *Nat. Rev. Drug Discov.*, 2013, **12**, 371-387.
7. A. K. Barczak and D. T. Hung, *Curr. Opin. Microbiol.*, 2009, **12**, 490-496.
8. *Antibiotic resistance threats in the United States, 2013*, U.S. Department of Health and Human Services: Centers for Disease Control and Prevention, 2013.
9. N. Ruiz, D. Kahne and T. J. Silhavy, *Nat. Rev. Microbiol.*, 2006, **4**, 57-66.
10. J. E. Cassat and E. P. Skaar, *Cell Host Microbe*, 2013, **13**, 509-519.
11. J. M. n. Roosenberg, Y.-M. Lin, Y. Lu and M. J. Miller, *Curr. Med. Chem.*, 2000, **7**, 159-197.
12. K. N. Raymond, E. A. Dertz and S. S. Kim, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 3584-3588.
13. N. C. Andrews and P. J. Schmidt, *Annu. Rev. Physiol.*, 2007, **69**, 69-85.
14. M. A. Fischbach, H. Lin, D. R. Liu and C. T. Walsh, *Nat. Chem. Biol.*, 2006, **2**, 132-138.
15. R. C. Hider and X. Kong, *Nat. Prod. Rep.*, 2010, **27**, 637-657.
16. K. Hantke, G. Nicholson, W. Rabsch and G. Winkelmann, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 3677-3682.
17. A. J. Bäumlér, R. M. Tsolis, A. W. M. van der Velden, I. Stojiljkovic, S. Anic and F. Heffron, *Gene*, 1996, **183**, 207-213.
18. A. J. Bäumlér, T. L. Norris, T. Lasco, W. Voigt, R. Reissbrodt, W. Rabsch and F. Heffron, *J. Bacteriol.*, 1998, **180**, 1446-1453.
19. M. A. Fischbach, H. Lin, L. Zhou, Y. Yu, R. J. Abergel, D. R. Liu, K. N. Raymond, B. L. Wanner, R. K. Strong, C. T. Walsh, A. Aderem and K. D. Smith, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 16502-16507.

20. M. Raffatellu, M. D. George, Y. Akiyama, M. J. Hornsby, S.-P. Nuccio, T. A. Paixao, B. P. Butler, H. Chu, R. L. Santos, T. Berger, T. W. Mak, R. M. Tsolis, C. L. Bevins, J. V. Solnick, S. Dandekar and A. J. Bäumlér, *Cell Host Microbe*, 2009, **5**, 476-486.
21. D. H. Goetz, M. A. Holmes, N. Borregaard, M. E. Bluhm, K. N. Raymond and R. K. Strong, *Molecular Cell*, 2002, **10**, 1033-1043.
22. T. H. Flo, K. D. Smith, S. Sato, D. J. Rodriguez, M. A. Holmes, R. K. Strong, S. Akira and A. Aderem, *Nature*, 2004, **432**, 917-921.
23. C. Ji, R. E. Juárez-Hernández and M. J. Miller, *Future Med. Chem.*, 2012, **4**, 297-313.
24. M. J. Miller, H. Zhu, Y. Xu, C. Wu, A. J. Walz, A. Vergne, J. M. Roosenberg, G. Moraski, A. A. Minnick, J. McKee-Dolence, J. Hu, K. Fennell, E. Kurt Dolence, L. Dong, S. Franzblau, F. Malouin and U. Möllmann, *Biometals*, 2009, **22**, 61-75.
25. G. L. Mislin and I. J. Schalk, *Metallomics*, 2014, **6**, 408-420.
26. H. Budzikiewicz, *Curr. Top. Med. Chem.*, 2001, **1**, 73-82.
27. V. Braun, *Drug Resist. Updat.*, 1999, **2**, 363-369.
28. N. Ohi, B. Aoki, K. Moro, T. Kuroki, N. Sugimura, T. Noto, T. Nehashi, M. Matsumoto, H. Okazaki and I. Matsunaga, *J. Antibiot.*, 1986, **39**, 242-250.
29. P. Silley, J. W. Griffiths, D. Monsey and A. M. Harris, *Antimicrob. Agents Chemother.*, 1990, **34**, 1806-1808.
30. T. Hashizume, M. Sanada, S. Nakagawa and N. Tanaka, *J. Antibiot.*, 1990, **43**, 1617-1620.
31. H. Nikaido and E. Rosenberg, *J. Bacteriol.*, 1990, **172**, 1361-1367.
32. J. A. Mckee, S. K. Sharma and M. J. Miller, *Bioconjug. Chem.*, 1991, **2**, 281-291.
33. N. A. C. Curtis, R. L. Eisenstadt, S. J. East, R. J. Cornford, L. A. Walker and A. J. White, *Antimicrob. Agents Chemother.*, 1988, **32**, 1879-1886.
34. M. S. Diarra, M. C. Lavoie, M. Jacques, I. Darwish, E. K. Dolence, J. A. Dolence, A. Ghosh, M. Ghosh, M. J. Miller and F. Malouin, *Antimicrob. Agents Chemother.*, 1996, **40**, 2610-2617.

35. S. Wittmann, M. Schnabelrauch, I. Scherlitz-Hofmann, U. Möllmann and D. Ankel-Fuchs, *Bioorg. Med. Chem.*, 2002, **10**, 1659-1670.
36. U. Möllmann, L. Heinisch, A. Bauernfeind, T. Köhler and D. Ankel-Fuchs, *Biomaterials*, 2009, **22**, 615-624.
37. S. Yoganathan, C. S. Sit and J. C. Vederas, *Org. Biomol. Chem.*, 2011, **9**, 2133-2141.
38. M. J. Miller, A. J. Walz, H. Zhu, C. Wu, G. Moraski, U. Möllmann, E. M. Tristani, A. L. Crumbliss, M. T. Ferdig, L. Checkley, R. L. Edwards and H. I. Boshoff, *J. Am. Chem. Soc.*, 2011, **133**, 2076-2079.
39. C. Ji, P. A. Miller and M. J. Miller, *J. Am. Chem. Soc.*, 2012, **134**, 9898-9901.
40. A. P. Tomaras, J. L. Crandon, C. J. McPherson, M. A. Banevicius, S. M. Finegan, R. L. Irvine, M. F. Brown, J. P. O'Donnell and D. P. Nicolau, *Antimicrob. Agents Chemother.*, 2013, **57**, 4197-4207.
41. T. A. Wencewicz, T. E. Long, U. Möllmann and M. J. Miller, *Bioconjug. Chem.*, 2013, **24**, 473-486.
42. T. A. Wencewicz and M. J. Miller, *J. Med. Chem.*, 2013, **56**, 4044-4052.
43. J. Starr, M. F. Brown, L. Aschenbrenner, N. Caspers, Y. Che, B. S. Gerstenberger, M. Huband, J. D. Knafels, M. M. Lemmon, C. Li, S. P. McCurdy, E. McElroy, M. R. Rauckhorst, A. P. Tomaras, J. A. Young, R. P. Zaniewski, V. Shanmugasundaram and S. Han, *J. Med. Chem.*, 2014, **57**, 384-355.
44. T. Zheng and E. M. Nolan, *J. Am. Chem. Soc.*, 2014, **136**, 9677-9691.
45. T. Zheng, J. L. Bullock and E. M. Nolan, *J. Am. Chem. Soc.*, 2012, **143**, 18388-18400.
46. J. K. Nicholson, E. Holmes, J. Kinross, R. Burcelin, G. Gibson, W. Jia and S. Petterson, *Science*, 2012, **336**, 1262-1267.
47. J. K. Nicholson and I. D. Wilson, *Nat. Rev. Drug Discov.*, 2003, **2**, 668-676.
48. S. I. Müller, M. Valdebenito and K. Hantke, *Biomaterials*, 2009, **22**, 691-695.
49. X. Yu, Y. Dai, T. Yang, M. R. Gagné and H. Gong, *Tetrahedron*, 2011, **67**, 144-151.

50. R. Lagos, M. Baeza, G. Corsini, C. Hetz, E. Strahsburger, J. A. Castillo, C. Vergara and O. Monasterio, *Mol. Microbiol.*, 2001, **42**, 229-243.
51. M. A. Fischbach, H. Lin, D. R. Liu and C. T. Walsh, *Proc. Natl. Acad. Sci. USA.*, 2005, **102**, 571-576.
52. E. M. Nolan, M. A. Fischbach, A. Koglin and C. T. Walsh, *J. Am. Chem. Soc.*, 2007, **129**, 14336-14347.
53. M. Luo, H. Lin, M. A. Fischbach, D. R. Liu, C. T. Walsh and J. T. Groves, *ACS Chem. Biol.*, 2006, **1**, 29-32.
54. W. R. Harris, C. J. Carrano, S. R. Cooper, S. R. Sofen, A. E. Avdeef, J. V. McArdle and K. N. Raymond, *J. Am. Chem. Soc.*, 1979, **101**, 6097-6104.
55. H. L. Mobley, D. M. Green, A. L. Trifillis, D. E. Johnson, G. R. Chippendale, C. V. Lockett, B. D. Jones and J. W. Warren, *Infect. Immun.*, 1990, **58**, 1281-1289.
56. M. A. Mulvey, J. D. Schilling and S. J. Hultgren, *Infect. Immun.*, 2001, **69**, 4572-4579.
57. R. A. Welch, V. Burland, G. Plunkett III, P. Redford, P. Roesch, D. Rasko, E. L. Buckles, S.-R. Liou, A. Boutin, J. Hackett, D. Stroud, G. F. Mayhew, D. J. Rose, S. Zhou, D. C. Schwartz, N. T. Perna, H. L. T. Mobley, M. S. Donnenberg and F. R. Blattner, *Proc. Natl. Acad. Sci. U. S. A.*, 2002, **99**, 17020-17024.
58. J. P. Henderson, J. R. Crowley, J. S. Pinkner, J. N. Walker, P. Tsukayama, W. E. Stamm, T. M. Hooton and S. J. Hultgren, *Plos Pathog.*, 2009, **5**, e1000305.
59. P. Kuhnert, J. Nicolet and J. Frey, *Appl. Environ. Microbiol.*, 1995, **61**, 4135-4139.
60. P. Daegelen, F. W. Studier, R. E. Lenski, S. Cure and J. F. Kim, *J. Mol. Biol.*, 2009, **394**, 634-643.
61. G. Reid and A. W. Bruce, *World J. Urol.*, 2006, **24**, 28-32.
62. M. A. J. Beerepoot, G. ter Riet, S. Nys, W. M. van der Wal, C. A. J. M. de Borgie, T. M. de Reijke, J. M. Prins, J. Koeijers, A. Verbon, E. Stobberingh and S. E. Geerlings, *Arch. Intern Med.*, 2012, **172**, 704-712.
63. E. D. Weinberg, *Perspect. Biol. Med.*, 1997, **40**, 578-583.

64. J. R. Bailey, C. S. J. Probert and T. A. Cogan, *PLoS One*, 2011, **6**, e26507.
65. M. G. Blango, E. M. Ott, A. Erman, P. Veranic and M. A. Mulvey, *PLoS One*, 2014, **9**, e93327.
66. I. Sekirov, S. L. Russell, L. C. Antunes and B. B. Finlay, *Physiol. Rev.*, 2010, **90**, 859-904.
67. F. Rafii, J. B. Sutherland and C. E. Cerniglia, *Ther. Clin. Risk Manag.*, 2008, **4**, 1343-1357.
68. L. J. Searle, G. Méric, I. Porcelli, S. K. Sheppard and S. Lucchini, *PLoS One*, 2015, **10**, e0117906.
69. A. L. Lloyd, D. A. Rasko and H. L. Mobley, *J. Bacteriol.*, 2007, **189**, 3532-3546.
70. S. L. Chen, M. Wu, J. P. Henderson, T. M. Hooton, M. E. Hibbing, S. J. Hultgren and J. I. Gordon, *Sci. Transl. Med.*, 2013, **5**, 184ra160.
71. S. Subashchandrabose and H. L. Mobley, *Metallomics*, 2015.
72. W. Rabsch, W. Voigt, R. Reissbrodt, R. M. Tsois and A. J. Bäuml, *J. Bacteriol.*, 1999, **181**, 3610-3612.
73. E. C. Garcia, A. R. Brumbaugh and H. L. T. Mobley, *Infect. Immun.*, 2011, **79**, 1225-1235.
74. T. J. Wiles, R. R. Kulesus and M. A. Mulvey, *Exp. Mol. Pathol.*, 2008, **85**, 11-19.
75. R. J. A. Ramirez, L. Karamanukyan, S. Ortiz and C. G. Gutierrez, *Tetrahedron Lett.*, 1997, **38**, 749-752.
76. R. C. Scarrow, D. J. Ecker, C. Ng, S. Liu and K. N. Raymond, *Inorg. Chem.*, 1991, **30**, 900-906.

Graphical Abstract

